Inhibitory effect of azelnidipine on sympathetic nerve activity in hypertensive patients Evaluation of different class effect of calcium channel blocker by using muscle sympathetic nerve activity

Inhibitory effect of azelnidipine on sympathetic nerve activity in hypertensive patients Evaluation of different class effect of calcium channel blocker by using muscle sympathetic nerve activity - Evaluation of sympathetic nerve activity in hypertensive patients, taking hypotensive drugs, azelnidipine or amlodipine, by using muscle sympathetic nerve activity

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000009123

Enrollment

Registered

2012-11-01

Start date

2012-01-06

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Primary Hypertension

Interventions

Calcium channel blocker(CCB), azelnidipine(16mg) will be taken for 8weeks, and then the other CCB, amlodipine(5mg) for next 8weeks. Evaluation of cardiovascular parameters and muscle sympathetic nerve

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Hypertensive patients who have not received any antihypertensive treatment with drugs or received antihypertensive treatment with drugs except any calcium channel blocker or beta blocker

Exclusion criteria

Exclusion criteria: 1.Patients who need drug medication for diabetes mellitus, heart failure or arrhythmia 2.Patients who have severe functional disturbance of liver or kidney 3.Patiens who have history of apoplexy or undergoing operation with artificial vessel 4.Patients of secondary hypertension 5.Patients whose systolic blood pressure is over 200mmHg or diastolic blood pressure is over 120mmHg

Design outcomes

Primary

Measure	Time frame
Each effect of azelnidipine and amlodipine on blood pressure and sympathetic nerve activity in hypertensive patients, 8 weeks after beginning of each administration	—

Secondary

Measure	Time frame
Each effect of azelnidipine and amlodipine on renal function, liver function, and cardiac function in hypertensive patients, 8 weeks after beginning of each administration	—

Countries

Japan

Contacts

Public ContactJun-ichiro Inomata

Internal Medicine, Kanazawa University Hospital Disease Control and Homeostasis

jinomataj@gmail.com076-265-2238

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026